Anteris Technologies Global Corp. (AVR)

Market Cap	648.33M +276.1%
Revenue (ttm)	2.24M -9.6%
Net Income	-103.56M
EPS	-1.62
Shares Out	97.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	972,548
Open	6.72
Previous Close	6.77
Day's Range	6.53 - 6.76
52-Week Range	3.30 - 11.06
Beta	0.73
Analysts	Buy
Price Target	14.00 (+110.53%)
Est. Earnings	Nov 11, 2026

About AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tiss...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 13, 2024
• Employees: 174
• Stock Exchange: Nasdaq
• Ticker Symbol: AVR
• Website: https://anteristech.com

Financial Performance

In 2025, AVR's revenue was $1.91 million, a decrease of -29.23% compared to the previous year's $2.70 million. Losses were -$94.14 million, 23.4% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for AVR stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 110.53% from the latest price.

Price Target

$14.0

(110.53% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 12, 2026

Data Sources Report a data error